Ц.Билэгтсайхан
Loading...
Товч нэр
Ц.Билэгтсайхан
Бүтэн нэр
Цолмон Билэгтсайхан
Латин нэр
Tsolmon Bilegtsaikhan
Албан тушаал
Проректор
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
7 results
Now showing 1 - 7 of 7
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Цар тахлын эхэн үед Монгол улсад голомтлон тархсан SARS-CoV-2-ийн удмын хэв шинжийг тодорхойлсон дүн(2023-02-16) ;Э.Мөнхтуяа ;Т.Сувд; ;Б.ОтгонжаргалБ.НоминҮндэслэл: SARS-CoV-2-ийн мутацийг илрүүлж удмын хэв шинжийг тодорхойлох нь тархвар зүйн болон эмнэлзүйн олон талын ач холбогдолтой болохыг судлаачид онцлон тэмдэглэжээ. Цар тахлын эхэн үед нуклейн хүчлийн дарааллыг тогтоох шинжилгээний хязгаарлагдмал байдлаас шалтгаалж Монгол улсад голомтлон тархсан шинэ коронавирусийн геномын судалгаа хомс хийгдсэн, мэдээ баримт дутмаг байгаа нь энэхүү судалгаа хийх үндэслэл боллоо. Зорилго: Монгол улсад голомтлон тархсан SARS-CoV-2-ийн удмын хэв шинжийг тогтоох. Арга, аргачлал: 2020 оны 11 дүгээр сараас 2021 оны 5 дугаар сар хүртэлх хугацаанд дотоодын халдварын батлагдсан тохиолдлын хадгалагдаж буй шинжлэгдэхүүнээс түүвэрлэн авч, SARS-CoV-2-ийн S генийн өвөрмөц мутацийг бодит хугацааны урвуу транскрипцийн полимеразын гинжин урвал (бх-УТ-ПГУ)-ын аргаар илрүүлж, вирусийн бүтэн геномын дарааллыг нанопор технологи (MinION Mk1C) ашиглан тогтоож EPI2ME программаар дүгнэлээ. Үр дүн: Судалгаанд батлагдсан тохиолдлын нийт 1656 шинжлэгдэхүүнийг хамруулан S генийн E484K, N501Y, HV69/70 делеци мутаци илрүүлэх бх-УТ-ПГУ-ын шинжилгээ хийхэд 91.3% (1512)-д дээрх мутациуд илрээгүй. Харин 5.4% (89)д N501Y, HV69/70 делецийн мутаци хавсран илэрсэн буюу Альфа хувилбар, 3.3% (55)-д E484K, N501Y, HV69/70 делецийн мутациуд хувилбарыг нь таамаглах боломжгүйгээр дангаар болон хавсарч илэрсэн. Вирусийн бүтэн геномын дараалал тогтоох шинжилгээг 342 тохиолдолд хийхэд (Alpha, V1) (B.1.1.7) хувилбар 2.3% (8)-ийг эзэлж байна. Харин 21C (Epsilon) (B.1.429), 19A, 20A хувилбар тус бүр 1-2 тохиолдолд илэрлээ. Дүгнэлт: 1. Монгол улсад 2020 оны 11 дүгээр сараас эхлэн 2021 оны 5 дугаар сар хүртэлх хугацаанд тархсан SARSCoV-2-ийн омгуудын дийлэнх нь S генийн E484K, N501Y, HV69/70 делеци мутаци агуулаагүй хувилбар байсан ба Alpha хувилбар 1 сараас эхлэн илэрсэн байна. 2. Монгол улсад цар тахлын эхэн үед SARS-CoV-2 –ийн 20В (B.1.1.46) хувилбар давамгайлан тархсан болох нь батлагдсан ба халдварлах чадамж өндөртэй Альфа хувилбар 2021 оны 1 дүгээр сараас эхлэн бүртгэгдэж эхэлсэн боловч нийгмийн эрүүл мэндийн арга хэмжээний дүнд тархалт нь харьцангуй хязгаарлагдаж байсан байна. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Сүрьеэтэй өвчтний коронавирүсийн (SARS-CoV-2) хавсарсан халдварын хүндрэлийн судалгаа(2022-12-26) ;Н.Цэрэннадмид ;Б.Цолмон ;Д.Гаравням; Э.ОюунчимэгҮндэслэл: Монгол Улс нь сүрьеэгийн тархалт өндөртэй дэлхийн 30 Ковид-19 улсын нэг юм. Сүрьеэгийн өвчлөлийн 100 000 хүн амд ноогдох түвшин Сүрьеэ Номхон далайн баруун бүсийн орнуудын дунд 4 дэх өндөр тархалттай Халдвар орон юм. 2019 оны 12 дугаар сард БНХАУ-ын Ухань хотод шинэ Нас баралтын төрлийн коронавирусийн дэгдэлт бүртгэгдэж, улмаар цар тахлын хүнд түвшин нөхцөл байдал үүссэн. Монгол Улсын хувьд 2022 оны 10 дугаар сарын 24 хүртэлх мэдээллээр 984,253 батлагдсан тохиолдол бүртгэгдэж улмаар 2,131 хүн нас баржээ. Коронавирусийн (SARS-CoV-2) батлагдсан 36 өвчтөн хамруулсан БНХАУ-н тохиолдол-хяналтын судалгаанд тохиолдлын 36.11% (n=13) бүлгийн 3 өвчтөн идэвхтэй хэлбэрийн сүрьеэтэй, 5 нь сүрьеэгээр өвчлөөд эдгэрсэн байжээ. Өмнө нь сүрьеэтэй гэж оношлогдоогүй 3 өвчтөний цээжний зурагт сүрьеэгийн хуучин шохойжилт илэрсэн ба 2 өвчтөнд далд хэлбэрийн сүрьеэ илэрсэн. Иймээс сүрьеэтэй өвчтөний дунд Коронавирусийн (SARS-CoV-2) халдварт өртсөн талаар судалгаа ховор, ялангуяа манай орны тухайд тус төрлийн судалгаа ховор байгаа нь энэхүү судалгааг хийх үндэслэл боллоо. Арга, аргачлал: Бид дескриптив судалгааны загвараар энэхүү судалгааг хийж гүйтцэтгэлээ. Судалгааны мэдээллийг цуглуулахдаа ХӨСҮТ-ийн сүрьеэгийн клиникийг түшиглэн асуумж болон халдварын бүртгэлийн нэгдсэн систем (www.tandalt.gerege.mn), сүрьеэгийн цахим бүртгэлийн нэгдсэн систем (tubis.mn)-ийн мэдээллийн сангаас тус тус цуглуулж, судалгааны үр дүнгийн тоон үзүүлэлтүүдийг SPSS-17 программ ашиглан боловсруулалт хийсэн. Судалгаа эхлүүлэх Ёс зүйн зөвшөөрлийг АШУҮИС-ийн Судалгааны Ёс зүйн хяналтын хорооноос авсан. (№2022/3-01) Үр дүн: Судалгаанд оролцогчдын 87.8% (n=63) УБ хотын, 12.2% (n=8) хөдөө орон нутгийн харьяалалтай, хүйсийн хувьд 40.9% (n=29) нь эрэгтэй, 59.1% (n=43) нь эмэгтэй, дундаж нас 37±14.7 жил байлаа. Коронавирус (SARS-CoV-2)-ийн болон сүрьеэгийн халдвартай өвчтөний 33.3% (n=22) хавсарсан өвчлөлтэй байгаагаас тоосонцорын харшилтай 18% (n=4), чихрийн шижин 5% (n=1), В,С вируст гепатит 36% (n=8), артерийн даралт ихсэлт 13.6% (n=3), уушгины архаг өвчтэй 13.6% (n=3), ходоод гэдэсний архаг өвчтэй 5% (n=1) болон бөөрний архаг өвчтэй 5% (n=1) байна. Судалгаанд оролцогч 72 өвчтнөөс 9% (n=6) нь нас барснаас хүйсийн хувьд 66.7% (n=4) эмэгтэй, 33.3% (n=2) эрэгтэй байсан ба сүрьеэгийн анх удаа оношлогдсон шинэ тохиолдол 5 (83.3%), сүрьеэгийн эмчилгээний хяналтын 16.7% (n=1) тохиолдол байна. Манай судалгаагаар коронавируст халдвар, сүрьеэ хавсарсан өвчтөний дунд нас баралтын түвшин CFR=6.7% байна. Дүгнэлт: 1. Коронавирус (SARS-CoV-2)-ийн болон сүрьеэгийн халдвартай өвчтөний 33.3% (n=22) хавсарсан өвчлөлтэй байна. 2. Сүрьеэтэй өвчтөнүүд Коронавирусийн (SARS-CoV-2) халдварын хүндрэлээс нас барах эрсдлийн түвшин 100 хүн тутамд 6.7 байгааг харуулж байна. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial(Elsevier BV, 2025-11) ;Batmunkh, Tsetsegsaikhan ;Neal, Eleanor F G ;Amraa, Otgonjargal ;Mazarakis, NadiaAltangerel, BolorBACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial(2026-04); ;Cook, Kaitlyn A ;Khudyakov, Polyna; BACKGROUND: Data from randomized controlled trials of vitamin D3 supplementation in modifying the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are sparse. OBJECTIVES: We evaluated the effect of vitamin D3 supplementation on healthcare utilization and other clinical outcomes among adults with coronavirus disease 2019 (COVID-19) and their close contacts. METHODS: We conducted a parallel 2-group randomized controlled double-blinded trial targeting free-living adults in the United States and Mongolia. Index participants with newly diagnosed COVID-19 were cluster-randomized with up to one of their cohabiting contacts either to an oral vitamin D3 loading dose of 9600 IU/d for 2 d followed by 3200 IU/d for 4 wk or to placebo. Participants completed weekly questionnaires on healthcare utilization, disease severity, and long COVID (index participants) or new SARS-CoV-2 infection (household contacts). The primary outcome was ≥1 healthcare visits (including hospitalization) or death within 4 wk among the index participants. RESULTS: Index participants (n = 1747) were a median of 38.0 y old (IQR: 31.1-47.0), 65.6% female/other sex, 4.2% Black non-Hispanic, 4.8% Hispanic/Latinx, 43.2% Asian, 44.3% non-Hispanic White, and 44.9% vitamin D deficient or insufficient (25-hydroxyvitamin D3 <20 ng/mL). Baseline characteristics for the household contacts (n = 277) were similar. The 4-wk cumulative incidence of healthcare utilization in index participants did not significantly differ between the vitamin D3 (n = 863) and placebo (n = 884) groups [cumulative incidences, 0.28 compared with 0.29; odds ratio (OR), 0.97; 95% confidence interval (CI): 0.75, 1.24]. Similar nonsignificant results were observed for the prespecified secondary treatment and prevention outcomes, though per-protocol analyses showed a nonsignificant trend toward benefit of vitamin D3 on the prevalence of long COVID at 8 wk (OR, 0.78; 95% CI: 0.59, 1.03). No safety concerns were identified. CONCLUSIONS: Among adults with newly diagnosed SARS-CoV-2 infections, vitamin D3 supplementation did not significantly change the 4-wk cumulative incidence of healthcare utilization or COVID-19-related outcomes compared with placebo. Promising results for long COVID warrant further study. This study was registered at clinicaltrials.gov as NCT04536298. First registered on 1 September, 2020.Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial(Elsevier BV, 2024-01) ;Batmunkh, Tsetsegsaikhan ;Moore, Kerryn A ;Thomson, Helen ;Altangerel, BolorAmraa, OtgonjargalBACKGROUND: COVID-19 vaccine booster doses restore vaccine effectiveness lost from waning immunity and emerging variants. Fractional dosing may improve COVID-19 booster acceptability and uptake and will reduce the per-dose cost of COVID-19 booster programmes. We sought to quantify the immunogenicity, reactogenicity, and safety of a half-dose BNT162b2 (Pfizer-BioNTech) booster relative to the standard formulation. METHODS: This randomised, controlled, non-inferiority trial recruited adults in Mongolia primed with a two-dose homologous ChAdOx1 nCov-19 (Oxford-AstraZeneca, n = 129 participants), BBIBP-CorV (Sinopharm (Beijing), n = 399), or Gam-COVID-Vac (Gamaleya, n = 70) schedule. Participants were randomised (1:1) to receive a 15 μg (half-dose) or 30 μg (full-dose) BNT162b2 booster. Participants and study staff assessing reactogenicity were blinded up to day 28. Co-primary endpoints were Wuhan-Hu-1 anti-spike S1 IgG seroresponse 28 days post-boosting and reactogenicity within 7 days of boosting. The non-inferiority margin for the absolute difference in seroresponse was -10%. Differences in seroresponse were estimated from logistic regression with marginal standardisation. Geometric mean ratios of IgG were also estimated. ClinicalTrials.gov Identifier: NCT05265065. FINDINGS: Between May 27th and September 30th, 2022, 601 participants were randomized to full-dose BNT162b2 (n = 300) or half-dose (n = 301). 598 were included in safety analyses, and 587 in immunological analyses. The frequency of grade 3-4 reactions was similar between arms (half-dose: 4/299 [1.3%]; full-dose: 6/299 [2.0%]). Across all severity grades, half-dose recipients reported fewer local and systemic reactions (60% versus 72% and 25% versus 32%, respectively). Seroresponse was 84.7% (250/295) and 86.6% (253/292) in the half-dose and full-dose arms, respectively (Difference: -2.8%; 95% CI -7.7, 2.1). Geometric mean IgG titres were similar in those receiving full and half-dose boosters for the ChAdOx1 and BBIBP-CorV primed groups, but lower in the half-dose arm in Gam-COVID-Vac-primed participants (GMR: 0.71; 95% CI 0.54, 0.93). INTERPRETATION: Half-dose BNT162b2 boosting elicited an immune response that was non-inferior to a full-dose, with fewer reactions, in adults primed with ChAdOx1 nCov-19 or BBIBP-CorV. Half-dose boosting may not be suitable in adults primed with Gam-COVID-Vac. Half-dose BNT162b2 boosting may be considered in populations primed with ChAdOx1 nCov-19 or BBIBP-CorV. FUNDING: Coalition for Epidemic Preparedness Innovations (CEPI).Scopus© Citations 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Molecular epidemiology of SARS-CoV-2 in Mongolia, first experience with nanopore sequencing in lower- and middle-income countries setting(Wiley, 2023-12); ; ; ; Burged, NatsagdorjBACKGROUND: Coronavirus disease (COVID-19) has had a significant impact globally, and extensive genomic research has been conducted on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage patterns and its variants. Mongolia's effective response resulted in low prevalence until vaccinations became available. However, due to the lack of systematically collected data and absence of whole genome sequencing capabilities, we conducted a two-stepped, nationally representative molecular epidemiologic study of SARS-CoV-2 in Mongolia for 2020 and 2021. METHODS: We used retrospective analysis of stored biological samples from November 2020 to October 2021 and a variant-specific real-time reverse transcription polymerase chain reaction (RT-PCR) test to detect SARS-CoV-2 variants, followed by whole genome sequencing by Nanopore technology. Samples were retrieved from different sites and stored at -70°C deep freezer, and tests were performed on samples with cycle threshold <30. RESULTS: Out of 4879 nucleic acid tests, 799 whole genome sequencing had been carried out. Among the stored samples of earlier local transmission, we found the 20B (B.1.1.46) variant predominated in the earlier local transmission period. A slower introduction and circulation of alpha and delta variants were observed compared to global dynamics in 2020 and 2021. Beta or Gamma variants were not detected between November 2020 and September 2021 in Mongolia. CONCLUSIONS: SARS-CoV-2 variants of concerns including alpha and delta were delayed in circulation potentially due to public health stringencies in Mongolia. We are sharing our initial experience with whole genome sequencing of SARS-CoV-2 from Mongolia, where sequencing data is sparse.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia(2026-09) ;Bazarjav, Purevbat ;Erdene-Ochir, Tseyenkhorloo ;Sandagdorj, Ankhbayar ;Enkhtuvshin, AltansukhEnkhbayar, PurevjargalBACKGROUND: Waning immunity after primary COVID-19 vaccination and the widespread use of heterogeneous vaccine platforms have created uncertainty regarding the durability of protection following booster vaccination. Mongolia implemented a mixed-platform vaccination program and deployed BNT162b2 as a booster. We evaluated the immunogenicity, effectiveness, and safety of a BNT162b2 booster following four primary vaccination regimens with 12 months follow-up. METHODS: In this prospective observational study in Ulaanbaatar, Mongolia, adults (≥18 years) who had completed a homologous two-dose primary series with BBIBP-CorV, ChAdOx1 nCoV-19, Gam-COVID-Vac, or BNT162b2 received a BNT162b2 booster a median of 189 days (IQR 186-215) after the second dose and were grouped according to their primary vaccination regimen. Humoral immune responses (anti-SARS-CoV-2 N/S1-RBD IgG, S-RBD IgG, and neutralizing antibodies) were measured at baseline and at multiple time points up to 12 months after booster vaccination. Reactogenicity was monitored for 28 days. SARS-CoV-2 infection was ascertained by a positive antigen/lateral-flow test and/or RT-PCR. VE was estimated for prespecified follow-up intervals by comparing the risk of SARS-CoV-2 infection in each boosted group with that in an unvaccinated comparison group. FINDINGS: Among 311 participants (mean age 41.88 years [SD 13.64]; 175 [56.27%] women and 136 [43.73%] men), antibody responses peaked at day 14 and declined through day 365 in all groups. At day 14, total antibody concentrations were highest in BNT + BNT (385.03 U/mL) and lowest in Gam + BNT (341.74 U/mL). S-RBD IgG at day 14 was highest in BNT + BNT (967.0 ng/mL) and lowest in BBIBP+BNT (863.70 ng/mL). Neutralizing antibodies at day 14 were highest in BNT + BNT (368.13 AU/mL) and BBIBP+BNT (336.70 AU/mL). During follow-up, 64 participants acquired SARS-CoV-2 infection and 15 (23.44%) were admitted to hospital. Reactogenicity was predominantly mild-to-moderate, and laboratory parameters were generally within acceptable ranges. Vaccine effectiveness declined from 1 month to 12 months: BBIBP+BNT 90.54% (95% CI 59.71-97.78) to 71.17% (39.66-86.23); ChAd+BNT 84.97% (49.75-95.51) to 52.59% (8.61-75.41); Gam + BNT 89.68% (23.95-98.60) to 63.84% (15.10-84.60); BNT + BNT 91.89% (40.06-98.90) to 72.29% (34.37-88.30). INTERPRETATION: A BNT162b2 booster following diverse primary COVID-19 vaccination regimens induced strong humoral responses that declined over 12 months and showed an acceptable reactogenicity profile. VE against SARS-CoV-2 infection was highest soon after boosting and lower later in follow-up. Although antibody levels and VE showed similar temporal patterns, these findings should be interpreted as complementary outcomes rather than evidence of a direct causal relationship or a formal immunological correlate of protection.
